Citigroup Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $84
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) but lowers the price target from $89 to $84.
May 23, 2024 | 5:27 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on CRISPR Therapeutics but lowers the price target from $89 to $84.
The maintained Buy rating suggests continued confidence in CRISPR Therapeutics' long-term prospects. However, the lowered price target indicates some caution, possibly due to recent performance or market conditions. The overall impact on the stock price is likely neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100